| Literature DB >> 29740211 |
Yuan Yuan1, Lin Wang1, Qing-Xiang Li1, Jian-Yun Zhang2, Zhi-Xiu Xu2, Chuan-Bin Guo1.
Abstract
BACKGROUND: Oropharyngeal squamous cell carcinoma (OPSCC) is an aggressive malignancy which has been investigated for decades and reported highly associated with the human papillomavirus (HPV) infection, yet there is no consensus reached on the optimal treatment paradigm. The relatively lower prevalence of HPV in China makes it important to evaluate the outcomes of HPV-negative OPSCC.Entities:
Keywords: HPV negative; cancer of oropharynx; lymph node metastasis; primary surgery; reconstruction
Year: 2018 PMID: 29740211 PMCID: PMC5931236 DOI: 10.2147/OTT.S156494
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Clinical characteristics of the 114 patients with HPV-negative primary oropharyngeal carcinoma
| Characteristics | No. of patients (%) |
|---|---|
| Age, years | |
| Median (range) | 55 (38–78) |
| ≤55 | 62 (54.4) |
| >55 | 52 (45.6) |
| Gender | |
| Male | 92 (80.7) |
| Female | 22 (19.3) |
| Smoking history | |
| Smoker | 82 (71.9) |
| Nonsmoker | 32 (28.1) |
| Alcohol history | |
| Drinker | 69 (60.5) |
| Nondrinker | 45 (39.5) |
| Tobacco and alcohol history | |
| Neither smoker nor drinker | 29 (25.4) |
| Smoker or drinker | 18 (15.8) |
| Smoker and drinker | 67 (58.8) |
| Site | |
| Base of tongue | 72 (63.2) |
| Soft palate | 27 (23.7) |
| Other oropharynx | 15 (13.1) |
| T stage | |
| T1 | 31 (27.2) |
| T2 | 47 (41.2) |
| T3 | 13 (11.4) |
| T4 | 23 (20.2) |
| Clinical N stage | |
| N0 | 62 (54.4) |
| N1 | 33 (28.9) |
| N2 | 18 (15.8) |
| N3 | 1 (0.9) |
| Growth pattern | |
| Exophytic | 27 (23.7) |
| Ulcerative | 45 (39.5) |
| Infiltrative | 42 (36.8) |
Abbreviation: HPV, human papillomavirus.
Tumor resection and reconstruction procedures according to T stage
| Lip-split approach
| Bone resection
| Tracheotomy
| Flap for reconstruction (number of patients)
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T stage | No | Yes | No | Yes | No | Yes | No | FA flap | ALT flap | Fibular flap | Rectus muscle flap | Submental flap | Pectoralis major myocutaneous flap |
| T1 | 23 | 8 | 29 | 2 | 21 | 10 | 22 | 7 | 2 | 0 | 0 | 0 | 0 |
| T2 | 21 | 26 | 35 | 12 | 10 | 37 | 16 | 25 | 1 | 1 | 2 | 3 | 0 |
| T3 | 4 | 9 | 8 | 5 | 1 | 12 | 0 | 11 | 1 | 0 | 0 | 0 | 2 |
| T4 | 5 | 18 | 12 | 11 | 2 | 21 | 1 | 13 | 6 | 2 | 0 | 0 | 1 |
Abbreviations: ALT, anterolateral thigh; FA, forearm.
Pathologic characteristics of the 114 patients
| Characteristics | No. of patients |
|---|---|
| N stage | |
| N+ | 61.3% (65/106) |
| N0 | 38.7% (41/106) |
| Differentiation grade | |
| Well | 14.0% (15/107) |
| Moderate | 71.0% (76/107) |
| Poor | 15.0% (16/107) |
| Infiltration depth | |
| ≤5 mm | 31.0% (27/87) |
| 5–10 mm | 21.9% (19/87) |
| >10 mm | 47.1% (41/87) |
| pTNM stage | |
| I | 8.5% (9/106) |
| II | 20.8% (22/106) |
| III | 29.2% (31/106) |
| IV | 41.5% (44/106) |
Notes:
N stage: pathologic nodal status. N+, positive neck; N0, negative neck.
Metastasis to the neck
| Metastasis area | Level I | Level II | Level III | Level IV | Level V | Total |
|---|---|---|---|---|---|---|
| Ipsilateral metastasis | ||||||
| No. of levels | 17/84 (20.2%) | 50/84 (59.5%) | 23/84 (27.4%) | 6/55 (10.9%) | 1/47 (2.1%) | 97/354 (27.4%) |
| No. of nodes | 21/587 (3.6%) | 83/745 (11.1%) | 42/742 (5.7%) | 14/449 (3.1%) | 3/392 (0.8%) | 163/2,915 (5.6%) |
| Contralateral metastasis | ||||||
| No. of levels | 2/43 (4.7%) | 4/41 (9.8%) | 3/41 (7.3%) | 0/22 | 1/20 (5%) | 10/167 (6.0%) |
| No. of nodes | 3/96 (3.1%) | 7/135 (5.2%) | 5/122 (4.1%) | 0/25 | 0/10 | 15/388 (3.9%) |
Figure 1The 3-year disease-specific survival rate of the 114 patients with HPV-negative oropharyngeal squamous cell carcinoma was 76.7%.
Abbreviation: HPV, human papillomavirus.
Figure 2Disease-specific survival rates of patients with HPV-negative oropharyngeal squamous cell carcinoma, comparing the clinicopathologic characteristics according to the Kaplan–Meier method.
Notes: (A) Disease-specific survival of the patients according to T stage. The survival rates in patients with T1 or T2 tumors were not significantly different (T1 vs T2, p=0.402). (B) Disease-specific survival of the patients according to N stage (N0 vs N1, p=0.036; N0 vs N1–3, p=0.002). (C) Disease-specific survival of the patients according to pTNM stage (pTNM1–2 vs pTNM3–4, p=0.002; pTNM1 vs pTNM2, p=0.134). (D) Disease-specific survival of the patients according to tumor differentiation. (E) Disease-specific survival of the patients according to the RT when adjusted by the pTNM stage (pTNM1–2/RT vs pTNM1–2/no RT, p=0.392; pTNM3–4/RT vs pTNM1–2/no RT, p=0.116; pTNM3–4/RT vs pTNM3–4/no RT, p=0.008). (F) Disease-specific survival of the male patients according to smoking and drinking exposure. The analysis was performed in male patients due to the absence of female drinker.
Abbreviations: HPV, human papillomavirus; RT, radiotherapy.
Univariate and multivariate analyses of the 3-year disease-specific survival rate
| Variables | HR | 95% CI | |
|---|---|---|---|
| T stage | |||
| T1–2 | |||
| T3–4 | 3.057 | 1.374–6.801 | 0.006 |
| N stage | |||
| N0 | |||
| N1 | 3.776 | 1.002–14.235 | 0.050 |
| N2a,2b | 6.226 | 1.606–24.132 | 0.008 |
| N2c,3 | 19.477 | 4.293–88.373 | <0.001 |
| pTNM stage | |||
| 1–2 | |||
| 3–4 | 11.747 | 1.579–87.410 | 0.016 |
| Differentiation | |||
| Well–moderate | |||
| Poor | 2.692 | 1.009–7.183 | 0.048 |
| T stage/RT | |||
| T1–2/no RT | |||
| T1–2/RT | 0.589 | 0.206–1.684 | 0.323 |
| T3–4/no RT | 3.083 | 1.033–9.203 | 0.044 |
| T3–4/RT | 1.727 | 0.546–5.465 | 0.352 |
| pTNM stage/RT | |||
| 1–2/no RT | |||
| 1–2/RT | 0.981 | ||
| 3–4/no RT | 13.402 | 1.712–104.914 | 0.013 |
| 3–4/RT | 4.419 | 0.570–34.235 | 0.155 |
| N stage/RT | |||
| N0/no RT | |||
| N0/RT | 2.331 | 0.211–25.709 | 0.490 |
| N+/no RT | 26.692 | 3.401–209.483 | 0.002 |
| N+/RT | 5.119 | 0.648–40.416 | 0.121 |
| N stage | |||
| N0 | |||
| N1 | 5.634 | 1.407–22.569 | 0.015 |
| N2a,2b | 12.916 | 2.952–56.516 | 0.001 |
| N2c,3 | 23.011 | 4.881–108.476 | <0.001 |
| RT | |||
| No RT | 3.992 | 1.514–10.523 | 0.005 |
Note: N0, pathologically negative neck; N+, pathologically positive neck.
Abbreviations: HR, hazard ratio; RT, radiotherapy.